Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Director | September 23, 2026 | September 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEKTAR THERAPEUTICS
Report date September 23, 2026 · Filed September 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,019 |
Reported balance
After 2026-09-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-23 · Grant · Acquired 2,000 · Balance 19,019 F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2: This RSU award vests in full, one year following September 23, 2026. F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $57.66 · Expires 2034-09-22 | Direct | 4,000 |
Reported balance
After 2026-09-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-23 · Grant · Acquired 4,000 · Balance 4,000 F5: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026. |
| Common StockSEC Table I · non-derivative | Indirectby daughter | 140 |
Reported balance
Holding disclosure · report date 2026-09-23 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 140 F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. F4: The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Indirectby son | 140 |
Reported balance
Holding disclosure · report date 2026-09-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 140 F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. F4: The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose. |
| Common stockSEC Table I · non-derivative | Indirectby daughter | 140 |
Reported balance
Holding disclosure · report date 2026-09-23 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 140 F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. F4: The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
F2: This RSU award vests in full, one year following September 23, 2026.
F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
F4: The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose.
F5: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Twist Bioscience Corp
Report date August 07, 2026 · Filed August 11, 2026
Section 16 reporting ended · disclosed 2026-02-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,084 |
Ending reported balance
After 2026-08-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-07 · Exercise / conversion · Acquired 18,417 · Balance 39,501 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2026. Row 2 · 2026-08-07 · Sale · Disposed 18,417 · Balance 21,084 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.89 · Expires 2028-09-13 | Direct | 0 |
Reported balance
After 2026-08-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-07 · Exercise / conversion · Disposed 18,417 · Balance 0 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2026. F3: The option is immediately exercisable. 10% of the shares subject to the option vested on September 13, 2018, 15% of the shares subject to the option vested on March 24, 2019, and 1/48th of the shares subject to the option vested on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy the Chess 1997 Trust | 42,528 |
Reported balance
Holding disclosure · report date 2026-08-07 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 42,528 F2: The Reporting Person and his spouse are the sole trustees and the sole beneficiaries of the Chess 1997 Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2026.
F2: The Reporting Person and his spouse are the sole trustees and the sole beneficiaries of the Chess 1997 Trust.
F3: The option is immediately exercisable. 10% of the shares subject to the option vested on September 13, 2018, 15% of the shares subject to the option vested on March 24, 2019, and 1/48th of the shares subject to the option vested on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 24, 2021 Filed Aug 26, 2021 23:01 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GiftCommon Stock | 6,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-053541 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,273 F1 · kind: This transaction involved a gift of shares by the reporting person to his children. Read SEC document |
| July 22, 2021 Filed Jul 22, 2021 23:13 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 91 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0001209191-21-047868 · doc4.xml · derivative · entry 9 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,279 Underlying: Common Stock · 91 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 22, 2021 Filed Jul 22, 2021 23:13 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 91 | $16.80 | $1,528.80 |
DisclosureSEC source: 0001209191-21-047868 · doc4.xml · nonDerivative · entry 6 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,573 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 22, 2021 Filed Jul 22, 2021 23:13 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 91 | $13.80 | $1,255.80 |
DisclosureSEC source: 0001209191-21-047868 · doc4.xml · nonDerivative · entry 5 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 21, 2021 Filed Jul 22, 2021 23:13 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 3,524 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0001209191-21-047868 · doc4.xml · derivative · entry 8 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,370 Underlying: Common Stock · 3,524 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 21, 2021 Filed Jul 22, 2021 23:13 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,524 | $16.81 | $59,238.44 |
DisclosureSEC source: 0001209191-21-047868 · doc4.xml · nonDerivative · entry 4 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,573 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $16.80 to $16.83. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| July 21, 2021 Filed Jul 22, 2021 23:13 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 3,524 | $13.80 | $48,631.20 |
DisclosureSEC source: 0001209191-21-047868 · doc4.xml · nonDerivative · entry 3 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 20, 2021 Filed Jul 22, 2021 23:13 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 2,106 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0001209191-21-047868 · doc4.xml · derivative · entry 7 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,894 Underlying: Common Stock · 2,106 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 20, 2021 Filed Jul 22, 2021 23:13 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 2,106 | $16.80 | $35,380.80 |
DisclosureSEC source: 0001209191-21-047868 · doc4.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,573 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.80 to $16.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| July 20, 2021 Filed Jul 22, 2021 23:13 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 2,106 | $13.80 | $29,062.80 |
DisclosureSEC source: 0001209191-21-047868 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 240 | $130.46 | $31,310.59 |
DisclosureSEC source: 0001214659-21-007500 · marketforms-53379.xml · nonDerivative · entry 6 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,014 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on February 12, 2021. F7 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $130.20 to $130.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 300 | $128.38 | $38,513.01 |
DisclosureSEC source: 0001214659-21-007500 · marketforms-53379.xml · nonDerivative · entry 5 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,254 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on February 12, 2021. F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $128.15 to $128.66 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 200 | $127.14 | $25,428.50 |
DisclosureSEC source: 0001214659-21-007500 · marketforms-53379.xml · nonDerivative · entry 4 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,554 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on February 12, 2021. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $127.08 to $127.21 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 155 | $126.00 | $19,529.71 |
DisclosureSEC source: 0001214659-21-007500 · marketforms-53379.xml · nonDerivative · entry 3 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,754 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on February 12, 2021. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $125.98 to $126.02 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,495 | $125.45 | $313,000.00 |
DisclosureSEC source: 0001214659-21-007500 · marketforms-53379.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,909 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on February 12, 2021. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $124.98 to $125.94 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 610 | $124.37 | $75,865.40 |
DisclosureSEC source: 0001214659-21-007500 · marketforms-53379.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,404 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on February 12, 2021. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $123.71 to $124.63 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 4,000 | $120.10 | $480,408.80 |
DisclosureSEC source: 0001214659-21-006944 · marketforms-53197.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,014 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on February 12, 2021. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $120.00 to $120.27 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 12, 2021 Filed May 14, 2021 22:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 8,000 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0001209191-21-032867 · doc4.xml · derivative · entry 3 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 8,000 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 12, 2021 Filed May 14, 2021 22:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 8,000 | $19.34 | $154,720.00 |
DisclosureSEC source: 0001209191-21-032867 · doc4.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,573 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.16 to $19.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| May 12, 2021 Filed May 14, 2021 22:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 8,000 | $13.80 | $110,400.00 |
DisclosureSEC source: 0001209191-21-032867 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 14, 2021 Filed Apr 16, 2021 22:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 8,000 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0001209191-21-027030 · doc4.xml · derivative · entry 3 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 8,000 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 14, 2021 Filed Apr 16, 2021 22:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 8,000 | $18.98 | $151,840.00 |
DisclosureSEC source: 0001209191-21-027030 · doc4.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,573 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.80 to $19.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| April 14, 2021 Filed Apr 16, 2021 22:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 8,000 | $13.80 | $110,400.00 |
DisclosureSEC source: 0001209191-21-027030 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 23:17 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 706 | $159.54 | $112,635.24 |
DisclosureSEC source: 0001214659-21-001483 · marketforms-51443.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,014 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 8, 2020. Read SEC document |
| February 03, 2021 Filed Feb 6, 2021 01:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantDirector Stock Option (right to buy) · Derivative | 973 | $0.00 Strike: $189.96 | $0.00 |
DisclosureSEC source: 0001214659-21-001429 · marketforms-51431.xml · derivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 973 Underlying: Common Stock · 973 shares Expires 2031-02-02 F2 · derivative.exercise_date: 100% of the shares subject to the option will vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 03, 2021 Filed Feb 6, 2021 01:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 486 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-001429 · marketforms-51431.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,720 F1 · shares: Represents a restricted stock unit award (the "RSU Award") of which 100% vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| September 25, 2020 Filed Sep 26, 2020 00:16 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 5,500 | $17.75 | $97,625.00 |
DisclosureSEC source: 0001209191-20-052159 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,573 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.52 to $18.13. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| September 22, 2020 Filed Sep 25, 2020 01:36 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 18,200 | $0.00 Strike: $18.91 | $0.00 |
DisclosureSEC source: 0001209191-20-052040 · doc4.xml · derivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,200 Underlying: Common Stock · 18,200 shares Expires 2028-09-21 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2020. Read SEC document |
| September 22, 2020 Filed Sep 25, 2020 01:36 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 9,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052040 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,073 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 22, 2020. Read SEC document |
| September 22, 2020 Filed Sep 26, 2020 00:11 UTC Amendment | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 18,200 | $0.00 Strike: $19.90 | $0.00 |
DisclosureSEC source: 0001209191-20-052152 · doc4a.xml · derivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,200 Underlying: Common Stock · 18,200 shares Expires 2028-09-21 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2020. Read SEC document |
| September 22, 2020 Filed Sep 26, 2020 00:11 UTC Amendment | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 9,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052152 · doc4a.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,073 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 22, 2020. Read SEC document |
| September 08, 2020 Filed Sep 11, 2020 00:19 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 8,000 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001209191-20-050074 · doc4.xml · derivative · entry 3 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2020-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 08, 2020 Filed Sep 11, 2020 00:19 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 8,000 | $18.53 | $148,240.00 |
DisclosureSEC source: 0001209191-20-050074 · doc4.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,973 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.37 to $18.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| September 08, 2020 Filed Sep 11, 2020 00:19 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 8,000 | $9.24 | $73,920.00 |
DisclosureSEC source: 0001209191-20-050074 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 23:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 8,000 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001209191-20-042219 · doc4.xml · derivative · entry 3 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2020-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 23:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 8,000 | $24.58 | $196,640.00 |
DisclosureSEC source: 0001209191-20-042219 · doc4.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,973 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $23.98 to $24.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 23:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 8,000 | $9.24 | $73,920.00 |
DisclosureSEC source: 0001209191-20-042219 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 22:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 8,000 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001209191-20-024928 · doc4.xml · derivative · entry 4 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 8,000 shares Expires 2020-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 22:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 197 | $19.02 | $3,746.94 |
DisclosureSEC source: 0001209191-20-024928 · doc4.xml · nonDerivative · entry 3 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,973 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $19.01 to $19.04. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 22:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 7,803 | $18.36 | $143,263.08 |
DisclosureSEC source: 0001209191-20-024928 · doc4.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,170 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.96 to $18.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 22:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 8,000 | $9.24 | $73,920.00 |
DisclosureSEC source: 0001209191-20-024928 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 22:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 8,000 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001209191-20-019011 · doc4.xml · derivative · entry 4 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 8,000 shares Expires 2020-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 22:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,200 | $17.41 | $20,892.00 |
DisclosureSEC source: 0001209191-20-019011 · doc4.xml · nonDerivative · entry 3 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,973 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $17.31 to $17.55. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 22:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 6,800 | $16.68 | $113,424.00 |
DisclosureSEC source: 0001209191-20-019011 · doc4.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,173 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.30 to $17.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 22:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 8,000 | $9.24 | $73,920.00 |
DisclosureSEC source: 0001209191-20-019011 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 15, 2020 00:00 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 8,000 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001209191-20-009818 · doc4.xml · derivative · entry 4 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 8,000 shares Expires 2020-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 15, 2020 00:00 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,599 | $23.72 | $85,368.28 |
DisclosureSEC source: 0001209191-20-009818 · doc4.xml · nonDerivative · entry 3 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,973 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $23.58 to $23.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 12, 2020 Filed Feb 15, 2020 00:00 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 4,401 | $23.32 | $102,631.32 |
DisclosureSEC source: 0001209191-20-009818 · doc4.xml · nonDerivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,572 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.56 to $23.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 12, 2020 Filed Feb 15, 2020 00:00 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 8,000 | $9.24 | $73,920.00 |
DisclosureSEC source: 0001209191-20-009818 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 04, 2020 Filed Feb 7, 2020 02:25 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantDirector Stock Option (right to buy) · Derivative | 5,648 | $0.00 Strike: $26.20 | $0.00 |
DisclosureSEC source: 0001214659-20-001013 · marketforms-47695.xml · derivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,648 Underlying: Common Stock · 5,648 shares Expires 2030-02-03 F2 · derivative.exercise_date: 100% of the shares subject to the option will vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.